Mode
Text Size
Log in / Sign up
Phase 2 N=29 Treatment

HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity

Sickle Cell Disease · Beta Thalassemia-Major

Enrolled (actual)
29
Serious AEs
10.3%
Results posted
Nov 2020
Primary outcome: Primary: Number of Participants With Sustained Cell Engraftment of Donor Cells — 29 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
alemtuzumab (Campath IH) (Drug); Fludarabine (Drug); Melphalan (Drug); Cyclosporine (Drug); Mycophenolate mofetil (Drug); Tacrolimus (Drug); Hematopoietic Stem Cell Transplantation (Biological)
Age
Pediatric, Adult · 1+ yrs
Sex
All
Sponsor
Northwell Health
Primary completion
Mar 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Sustained Cell Engraftment of Donor Cells
29
SECONDARY
Assessment of Treatment Related Mortality and Morbidity
13; 9; 7
SECONDARY
Event Free Survival; Number of Participants Who Survived at 2 Years
1; 2; 26

Summary

This study will evaluate the use of reduced intensity conditioning regimen in patients with high risk hemoglobinopathy Sickle Cell and B-Thalassemia Major in combination with standard immunosuppressive medications, followed by a routine stem cell transplant in order to assess whether or not it is as effective as myeloablative high dose chemotherapy and transplant.

Eligibility Criteria

Inclusion Criteria

  • Patient Inclusion Criteria for Sickle Cell Disease
  • Patients at least one year of age to less than or equal to 21 years of age with (Sickle Cell Disease-SS or Sickle Cell-S-β-Thalassemia and with one or more of the following disease complications:
  • Development of stroke on chronic transfusion protocol.
  • Allosensitization on chronic transfusion therapy
  • Impaired neuropsychological function and abnormal MRI scan
  • Abnormal Transcranial Doppler studies
  • Acute chest syndrome (2 to 3 episodes of acute chest syndrome in last 3 to 4 years).
  • Ferritin level < 1500 mg/ml
  • Recurrent painful priapism; 3-4 episodes/year requiring intervention.
  • Recurrent vaso-occlusive crisis of at least 3 to 4 episodes/year.
  • Osteonecrosis of multiple bones with documented destructive changes.
  • Signed informed consent
  • Patients physically and psychologically capable of undergoing transplantation and a period of strict isolation.
  • Ferritin < 1500
  • Liver Iron Concentration < 6mg/g

Patient Inclusion Criteria for β Thalassemia major Patients less than or equal to 21 years of age with B- Thalassemia major on routine monthly transfusion protocol or with one or more of the following complications;

  • Hepatomegaly.
  • Liver biopsy revealing evidence of portal fibrosis as A) Mild B) Moderate
  • Ferritin level≤ 1500ng/ml
  • Liver Iron Concentration (LIC) < 6mg/g

Exclusion Criteria

  • Exclusion Criteria for Both Sickle Cell and β Thalassemia Major Patient
  • HIV positive result confirmed by Western Blot.
  • Pregnancy (Pregnancy testing for females of child-bearing age will be performed and those with a positive serum β-Human Chorionic Gonadotropin will be excluded) and lactating females.
  • Creatinine greater than two times the upper limit of normal for the laboratory,
  • Pulmonary disease with FVC, FEV1 or DLCO parameters < 50% predicted (corrected for hemoglobin) or stage 3 or 4 sickle lung disease.
  • Cardiac insufficiency or coronary artery disease requiring treatment
  • Active infection requiring systemic antibiotic therapy with antibacterial, antifungal or antiviral agents
  • Lansky performance score <70%- (Appendix B)
  • Acute hepatitis/biopsy evidence of cirrhosis.
  • Pulmonary Hypertension
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02435901). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search